VitaLonga

Review of studies · Supplements / medicine · 17 Nov 2026

Across 64 Middle East and North Africa trials, intermediate vitamin D doses raised 25(OH)D, and higher doses added less

Source: Osteoporosis International

What the research found

An updated systematic review and meta-analysis of randomized trials was published online on 17 November 2026. It pooled oral vitamin D supplementation of at least 3 months in adults and elderly people in the Middle East and North Africa. Sixty-four trials were included, 61 in adults and 3 in elderly people. Weighted mean baseline 25-hydroxyvitamin D was 19.5 ng/ml in adults and 14.5 ng/ml in elderly people. The abstract does not give age or sex beyond that. High doses above 2,000 IU a day, versus placebo, raised the level by 19.4 ng/ml (42 trials, 95 percent CI 16.5 to 22.3), graded as low-level evidence. The share reaching at least 20 ng/ml was 92 percent on that high dose and 47.3 percent in pooled placebo arms. Intermediate doses of 800 to 2,000 IU a day raised the level by 9.5 ng/ml (6.5 to 12.5), also graded low-level evidence, with 82.5 percent reaching at least 20 ng/ml. Each extra 100 IU a day lined up with 0.4 ng/ml. Baseline level, body mass index, and dose predicted the response. Reports of adverse events were limited. The authors say 1,000 to 2,000 IU a day was enough for most people in these trials to reach 20 ng/ml, and that higher doses added little. That is a regional evidence summary, not a personal dosing plan. DOI 10.1007/s00198-026-08257-2. Not medical advice.

Evidence level: Review of studies. This is among the stronger kinds of evidence, but one study rarely settles a question.

Read the original at Osteoporosis International

More supplements / medicine news